Swiss drugmaker Roche plans to work with U.S. firm Seaside Therapeutics to develop treatments for autism spectrum disorders and fragile X syndrome that differ fundamentally from other methods by targeting their molecular basis
via http://www.foxnews.com/health/2012/06/19/roche-in-deal-to-treat-root-cause-autism/?
via http://www.foxnews.com/health/2012/06/19/roche-in-deal-to-treat-root-cause-autism/?
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.